Distinct signatures of the immune responses in low risk versus high risk neuroblastoma

Madhu Gowda, Kamar Godder, Maciej Kmieciak, Andrea Worschech, Maria Libera Ascierto, Ena Wang, Francesco M. Marincola, Masoud H. Manjili

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Background: Over 90% of low risk (LR) neuroblastoma patients survive whereas less than 30% of high risk (HR) patients are long term survivors. Age (children younger than 18 months old) is associated with LR disease. Considering that adaptive immune system is well developed in older children, and that T cells were shown to be involved in tumor escape and progression of cancers, we sought to determine whether HR patients may tend to show a signature of adaptive immune responses compared to LR patients who tend to have diminished T-cell responses but an intact innate immune response.Methods: We performed microarray analysis of RNA extracted from the tumor specimens of HR and LR patients. Flow cytometry was performed to determine the cellular constituents in the blood while multiplex cytokine array was used to detect the cytokine profile in patients' sera. A HR tumor cell line, SK-N-SH, was also used for detecting the response to IL-1β, a cytokines which is involved in the innate immune responses.Results: Distinct patterns of gene expression were detected in HR and LR patients indicating an active T-cell response and a diminished adaptive immune response, respectively. A diminished adaptive immune response in LR patients was evident by higher levels of IL-10 in the sera. In addition, HR patients had lower levels of circulating myeloid derived suppressor cells (MDSC) compared with a control LR patient. LR patients showed slightly higher levels of cytokines of the innate immune responses. Treatment of the HR tumor line with IL-1β induced expression of cytokines of the innate immune responses.Conclusions: This data suggests that adaptive immune responses may play an important role in the progression of HR disease whereas innate immune responses may be active in LR patients.

Original languageEnglish
Article number170
JournalJournal of Translational Medicine
Volume9
Issue number1
DOIs
Publication statusPublished - 6 Oct 2011
Externally publishedYes

Fingerprint

Neuroblastoma
Innate Immunity
Adaptive Immunity
T-cells
Cytokines
Tumors
T-Lymphocytes
Interleukin-1
Tumor Escape
Neoplasms
Flow cytometry
Immune system
Microarray Analysis
Microarrays
Tumor Cell Line
Serum
Gene expression
Interleukin-10
Survivors
Immune System

Keywords

  • Adaptive immunity
  • Innate immunity
  • Neuroblastoma
  • Prognostic biomarkers

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Gowda, M., Godder, K., Kmieciak, M., Worschech, A., Ascierto, M. L., Wang, E., ... Manjili, M. H. (2011). Distinct signatures of the immune responses in low risk versus high risk neuroblastoma. Journal of Translational Medicine, 9(1), [170]. https://doi.org/10.1186/1479-5876-9-170

Distinct signatures of the immune responses in low risk versus high risk neuroblastoma. / Gowda, Madhu; Godder, Kamar; Kmieciak, Maciej; Worschech, Andrea; Ascierto, Maria Libera; Wang, Ena; Marincola, Francesco M.; Manjili, Masoud H.

In: Journal of Translational Medicine, Vol. 9, No. 1, 170, 06.10.2011.

Research output: Contribution to journalArticle

Gowda, M, Godder, K, Kmieciak, M, Worschech, A, Ascierto, ML, Wang, E, Marincola, FM & Manjili, MH 2011, 'Distinct signatures of the immune responses in low risk versus high risk neuroblastoma', Journal of Translational Medicine, vol. 9, no. 1, 170. https://doi.org/10.1186/1479-5876-9-170
Gowda, Madhu ; Godder, Kamar ; Kmieciak, Maciej ; Worschech, Andrea ; Ascierto, Maria Libera ; Wang, Ena ; Marincola, Francesco M. ; Manjili, Masoud H. / Distinct signatures of the immune responses in low risk versus high risk neuroblastoma. In: Journal of Translational Medicine. 2011 ; Vol. 9, No. 1.
@article{803a73f3884e4f45b4ecb6e777677cf2,
title = "Distinct signatures of the immune responses in low risk versus high risk neuroblastoma",
abstract = "Background: Over 90{\%} of low risk (LR) neuroblastoma patients survive whereas less than 30{\%} of high risk (HR) patients are long term survivors. Age (children younger than 18 months old) is associated with LR disease. Considering that adaptive immune system is well developed in older children, and that T cells were shown to be involved in tumor escape and progression of cancers, we sought to determine whether HR patients may tend to show a signature of adaptive immune responses compared to LR patients who tend to have diminished T-cell responses but an intact innate immune response.Methods: We performed microarray analysis of RNA extracted from the tumor specimens of HR and LR patients. Flow cytometry was performed to determine the cellular constituents in the blood while multiplex cytokine array was used to detect the cytokine profile in patients' sera. A HR tumor cell line, SK-N-SH, was also used for detecting the response to IL-1β, a cytokines which is involved in the innate immune responses.Results: Distinct patterns of gene expression were detected in HR and LR patients indicating an active T-cell response and a diminished adaptive immune response, respectively. A diminished adaptive immune response in LR patients was evident by higher levels of IL-10 in the sera. In addition, HR patients had lower levels of circulating myeloid derived suppressor cells (MDSC) compared with a control LR patient. LR patients showed slightly higher levels of cytokines of the innate immune responses. Treatment of the HR tumor line with IL-1β induced expression of cytokines of the innate immune responses.Conclusions: This data suggests that adaptive immune responses may play an important role in the progression of HR disease whereas innate immune responses may be active in LR patients.",
keywords = "Adaptive immunity, Innate immunity, Neuroblastoma, Prognostic biomarkers",
author = "Madhu Gowda and Kamar Godder and Maciej Kmieciak and Andrea Worschech and Ascierto, {Maria Libera} and Ena Wang and Marincola, {Francesco M.} and Manjili, {Masoud H.}",
year = "2011",
month = "10",
day = "6",
doi = "10.1186/1479-5876-9-170",
language = "English",
volume = "9",
journal = "Journal of Translational Medicine",
issn = "1479-5876",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Distinct signatures of the immune responses in low risk versus high risk neuroblastoma

AU - Gowda, Madhu

AU - Godder, Kamar

AU - Kmieciak, Maciej

AU - Worschech, Andrea

AU - Ascierto, Maria Libera

AU - Wang, Ena

AU - Marincola, Francesco M.

AU - Manjili, Masoud H.

PY - 2011/10/6

Y1 - 2011/10/6

N2 - Background: Over 90% of low risk (LR) neuroblastoma patients survive whereas less than 30% of high risk (HR) patients are long term survivors. Age (children younger than 18 months old) is associated with LR disease. Considering that adaptive immune system is well developed in older children, and that T cells were shown to be involved in tumor escape and progression of cancers, we sought to determine whether HR patients may tend to show a signature of adaptive immune responses compared to LR patients who tend to have diminished T-cell responses but an intact innate immune response.Methods: We performed microarray analysis of RNA extracted from the tumor specimens of HR and LR patients. Flow cytometry was performed to determine the cellular constituents in the blood while multiplex cytokine array was used to detect the cytokine profile in patients' sera. A HR tumor cell line, SK-N-SH, was also used for detecting the response to IL-1β, a cytokines which is involved in the innate immune responses.Results: Distinct patterns of gene expression were detected in HR and LR patients indicating an active T-cell response and a diminished adaptive immune response, respectively. A diminished adaptive immune response in LR patients was evident by higher levels of IL-10 in the sera. In addition, HR patients had lower levels of circulating myeloid derived suppressor cells (MDSC) compared with a control LR patient. LR patients showed slightly higher levels of cytokines of the innate immune responses. Treatment of the HR tumor line with IL-1β induced expression of cytokines of the innate immune responses.Conclusions: This data suggests that adaptive immune responses may play an important role in the progression of HR disease whereas innate immune responses may be active in LR patients.

AB - Background: Over 90% of low risk (LR) neuroblastoma patients survive whereas less than 30% of high risk (HR) patients are long term survivors. Age (children younger than 18 months old) is associated with LR disease. Considering that adaptive immune system is well developed in older children, and that T cells were shown to be involved in tumor escape and progression of cancers, we sought to determine whether HR patients may tend to show a signature of adaptive immune responses compared to LR patients who tend to have diminished T-cell responses but an intact innate immune response.Methods: We performed microarray analysis of RNA extracted from the tumor specimens of HR and LR patients. Flow cytometry was performed to determine the cellular constituents in the blood while multiplex cytokine array was used to detect the cytokine profile in patients' sera. A HR tumor cell line, SK-N-SH, was also used for detecting the response to IL-1β, a cytokines which is involved in the innate immune responses.Results: Distinct patterns of gene expression were detected in HR and LR patients indicating an active T-cell response and a diminished adaptive immune response, respectively. A diminished adaptive immune response in LR patients was evident by higher levels of IL-10 in the sera. In addition, HR patients had lower levels of circulating myeloid derived suppressor cells (MDSC) compared with a control LR patient. LR patients showed slightly higher levels of cytokines of the innate immune responses. Treatment of the HR tumor line with IL-1β induced expression of cytokines of the innate immune responses.Conclusions: This data suggests that adaptive immune responses may play an important role in the progression of HR disease whereas innate immune responses may be active in LR patients.

KW - Adaptive immunity

KW - Innate immunity

KW - Neuroblastoma

KW - Prognostic biomarkers

UR - http://www.scopus.com/inward/record.url?scp=80053533851&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80053533851&partnerID=8YFLogxK

U2 - 10.1186/1479-5876-9-170

DO - 10.1186/1479-5876-9-170

M3 - Article

VL - 9

JO - Journal of Translational Medicine

JF - Journal of Translational Medicine

SN - 1479-5876

IS - 1

M1 - 170

ER -